MedTrace Logo

Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT

NCT04952350 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2021-10-25

No results posted yet for this study

Summary

This randomized placebo-controlled double-blinded clinical trial aims to test the efficacy of administering atorvastatin 40 mg to hospitalized COVID-19 patients for 28 days on the all-cause 28-day mortality.

Conditions

Interventions

DRUG

Atorvastatin 40 Mg Oral Tablet

Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.

OTHER

Placebo

A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Moataz M Emara, MD, EDAIC · Mansoura University - Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-14
Primary Completion
2021-11-30
Completion
2022-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952350 on ClinicalTrials.gov